drugset / Trial / NCT01179529

Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

NCT01179529

Phase 2 Completed Technical University of Munich
NaSingle-groupTreatment

Summary

This study aims at evaluating the therapeutic potential of omalizumab in atopic dermatitis, and to work out biomarkers predictive of treatment response.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody

Indications